[HTML][HTML] Targeting the PDGF signaling pathway in tumor treatment

CH Heldin - Cell Communication and Signaling, 2013 - Springer
Platelet-derived growth factor (PDGF) isoforms and PDGF receptors have important
functions in the regulation of growth and survival of certain cell types during embryonal …

RET revisited: expanding the oncogenic portfolio

LM Mulligan - Nature Reviews Cancer, 2014 - nature.com
The RET receptor tyrosine kinase is crucial for normal development but also contributes to
pathologies that reflect both the loss and the gain of RET function. Activation of RET occurs …

Mechanical induction of the tumorigenic β-catenin pathway by tumour growth pressure

ME Fernandez-Sanchez, S Barbier, J Whitehead… - Nature, 2015 - nature.com
The tumour microenvironment may contribute to tumorigenesis owing to mechanical forces
such as fibrotic stiffness or mechanical pressure caused by the expansion of hyper …

Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies

FH Tan, TL Putoczki, SS Stylli… - OncoTargets and therapy, 2019 - Taylor & Francis
Human malignancies are often the result of overexpressed and constitutively active receptor
and non-receptor tyrosine kinases, which ultimately lead to the mediation of key tumor …

[HTML][HTML] Novel 1, 2, 4-oxadiazole derivatives in drug discovery

K Biernacki, M Daśko, O Ciupak, K Kubiński, J Rachon… - Pharmaceuticals, 2020 - mdpi.com
Five-membered 1, 2, 4-oxadiazole heterocyclic ring has received considerable attention
because of its unique bioisosteric properties and an unusually wide spectrum of biological …

[HTML][HTML] Clinical and translational implications of RET rearrangements in non–small cell lung cancer

R Ferrara, N Auger, E Auclin, B Besse - Journal of Thoracic Oncology, 2018 - Elsevier
Since the discovery in 2012 of rearranged during transfection proto-oncogene gene (RET)
rearrangements in NSCLC, at least 12 different fusion variants have been identified, with …

[HTML][HTML] The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets

E Medico, M Russo, G Picco, C Cancelliere… - Nature …, 2015 - nature.com
The development of molecularly targeted anticancer agents relies on large panels of tumour-
specific preclinical models closely recapitulating the molecular heterogeneity observed in …

Ponatinib: An update on its drug targets, therapeutic potential and safety

Y Gao, Y Ding, X Tai, C Zhang, D Wang - Biochimica et Biophysica Acta …, 2023 - Elsevier
Leukemia is a malignancy of the hematopoietic system, and as its pathogenesis has
become better understood, three generations of tyrosine kinase inhibitors (TKIs) have been …

[HTML][HTML] Current guidelines for management of medullary thyroid carcinoma

M Kim, BH Kim - Endocrinology and Metabolism, 2021 - synapse.koreamed.org
Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor originating from the
parafollicular cells. The diagnostic and therapeutic strategies for the condition are different …

[HTML][HTML] Thyroid cancers: from surgery to current and future systemic therapies through their molecular identities

L Lorusso, V Cappagli, L Valerio, C Giani… - International Journal of …, 2021 - mdpi.com
Differentiated thyroid cancers (DTC) are commonly and successfully treated with total
thyroidectomy plus/minus radioiodine therapy (RAI). Medullary thyroid cancer (MTC) is only …